---
figid: PMC3523565__dddt-6-391f1
figlink: /pmc/articles/PMC3523565/figure/f1-dddt-6-391/
number: Figure 1
caption: 'Simplified scheme of the mitogen-activated protein kinase (MAPK) (RAS-RAF-MEK-ERK)
  signaling pathway.Notes:BRAF and NRAS are the most commonly mutated oncogenes in
  melanoma. Downstream effectors of the pathway lead to increased survival and proliferation
  by various mechanisms (eg, increased transcription of genes and regulation of apoptotic
  proteins). Potential mechanisms of acquired resistance to BRAF inhibitor therapy
  are highlighted in red. BRAF inhibition can lead to activation of the MAPK pathway
  via acquisition of secondary NRAS Q61K mutations; RAF isoform signal switching (ARAF
  > BRAF > CRAF); truncation of BRAF, resulting in a form that is resistant to the
  inhibitor; amplification of BRAF; MEK1 C121S mutation; and increased expression
  of COT, a partner kinase.Abbreviations: PDGFRB, platelet-derived growth factor receptor
  beta; IGF-1R, insulin-like growth factor 1 receptor.'
pmcid: PMC3523565
papertitle: Dabrafenib and its potential for the treatment of metastatic melanoma.
reftext: Alexander M Menzies, et al. Drug Des Devel Ther. 2012;6:391-405.
pmc_ranked_result_index: '126509'
pathway_score: 0.9279165
filename: dddt-6-391f1.jpg
figtitle: Simplified scheme of the mitogen-activated protein kinase (MAPK) (RAS-RAF-MEK-ERK)
  signaling pathway.Notes:BRAF and NRAS are the most commonly mutated oncogenes in
  melanoma
year: '2012'
organisms: Homo sapiens
ndex: c6bf7d2e-debb-11ea-99da-0ac135e8bacf
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC3523565__dddt-6-391f1.html
  '@type': Dataset
  description: 'Simplified scheme of the mitogen-activated protein kinase (MAPK) (RAS-RAF-MEK-ERK)
    signaling pathway.Notes:BRAF and NRAS are the most commonly mutated oncogenes
    in melanoma. Downstream effectors of the pathway lead to increased survival and
    proliferation by various mechanisms (eg, increased transcription of genes and
    regulation of apoptotic proteins). Potential mechanisms of acquired resistance
    to BRAF inhibitor therapy are highlighted in red. BRAF inhibition can lead to
    activation of the MAPK pathway via acquisition of secondary NRAS Q61K mutations;
    RAF isoform signal switching (ARAF > BRAF > CRAF); truncation of BRAF, resulting
    in a form that is resistant to the inhibitor; amplification of BRAF; MEK1 C121S
    mutation; and increased expression of COT, a partner kinase.Abbreviations: PDGFRB,
    platelet-derived growth factor receptor beta; IGF-1R, insulin-like growth factor
    1 receptor.'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - PIK3CA
  - PIK3R5
  - PIK3R3
  - BRAF
  - PIK3CG
  - AKT2
  - MAPK3
  - PIK3R4
  - RAF1
  - AKT1
  - PDGFRB
  - PIK3CD
  - MTOR
  - MAP2K2
  - NRAS
  - ARAF
  - PIK3R6
  - AKT3
  - HRAS
  - PIK3CB
  - PTEN
  - MAPK1
  - MAP2K1
  - IGF1R
  - KRAS
  - tyrosine
  - Cancer
  - Cardiomyopathy
  - Lung cancer
  - Noonan syndrome
genes:
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CA
  entrez: '5290'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R5
  entrez: '23533'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R3
  entrez: '8503'
- word: BRAF-
  symbol: BRAF
  source: hgnc_symbol
  hgnc_symbol: BRAF
  entrez: '673'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CG
  entrez: '5294'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT2
  entrez: '208'
- word: ERK1/2
  symbol: ERK1
  source: hgnc_alias_symbol
  hgnc_symbol: MAPK3
  entrez: '5595'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R4
  entrez: '30849'
- word: CRAF,
  symbol: c-Raf
  source: hgnc_alias_symbol
  hgnc_symbol: RAF1
  entrez: '5894'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT1
  entrez: '207'
- word: PDGFRB
  symbol: PDGFRB
  source: hgnc_symbol
  hgnc_symbol: PDGFRB
  entrez: '5159'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CD
  entrez: '5293'
- word: MTOR
  symbol: MTOR
  source: hgnc_symbol
  hgnc_symbol: MTOR
  entrez: '2475'
- word: MEK1/2
  symbol: MEK2
  source: hgnc_alias_symbol
  hgnc_symbol: MAP2K2
  entrez: '5605'
- word: NRAS
  symbol: NRAS
  source: hgnc_symbol
  hgnc_symbol: NRAS
  entrez: '4893'
- word: ARAF,
  symbol: ARAF
  source: hgnc_symbol
  hgnc_symbol: ARAF
  entrez: '369'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R6
  entrez: '146850'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: NRAS
  entrez: '4893'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT3
  entrez: '10000'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: HRAS
  entrez: '3265'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CB
  entrez: '5291'
- word: PTEN
  symbol: PTEN
  source: hgnc_symbol
  hgnc_symbol: PTEN
  entrez: '5728'
- word: ERK1/2
  symbol: ERK2
  source: hgnc_alias_symbol
  hgnc_symbol: MAPK1
  entrez: '5594'
- word: MEK1
  symbol: MEK1
  source: hgnc_alias_symbol
  hgnc_symbol: MAP2K1
  entrez: '5604'
- word: IGF-1R,
  symbol: IGF1R
  source: hgnc_symbol
  hgnc_symbol: IGF1R
  entrez: '3480'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: KRAS
  entrez: '3845'
chemicals:
- word: tyrosine
  source: MESH
  identifier: D014443
diseases:
- word: Cancer
  source: ''
  identifier: ''
- word: Cardiomyopathy
  source: ''
  identifier: ''
- word: Lung cancer
  source: ''
  identifier: ''
- word: Noonan syndrome
  source: ''
  identifier: ''
---
